Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial.
Saved in:
| Title: | Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial. |
|---|---|
| Authors: | Chew KW; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA., Taiwo BO; Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Moser C; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Daar ES; Lundquist Institute, Harbor-University of California, Los Angeles Medical Center, Torrance, California, USA., Wohl DA; Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Ritz J; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Javan AC; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Li JZ; Department of Medicine, Harvard Medical School, Cambridge, Massachusetts, USA., Fischer W; Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Greninger AL; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, Washington, USA., Bausch C; SAB Biotherapeutics, Inc, Sioux Falls, South Dakota, USA., Luke T; SAB Biotherapeutics, Inc, Sioux Falls, South Dakota, USA., Call R; Clinical Research Partners, Richmond, Virginia, USA., Neytman G; Quantum Clinical Trials, Miami, Florida, USA., Giganti MJ; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Fletcher CV; Center for Drug Discovery, University of Nebraska Medical Center, Omaha, Nebraska, USA., Hughes MD; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Eron JJ; Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Currier JS; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA., Smith DM; Department of Medicine, University of California, San Diego, La Jolla, California, USA. |
| Corporate Authors: | ACTIV-2/A5401 Study Team |
| Source: | The Journal of infectious diseases [J Infect Dis] 2024 Nov 15; Vol. 230 (5), pp. 1177-1186. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
